The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 26, 2018
Filed:
Dec. 21, 2017
Applicant:
Avalanche Australia Pty Ltd., Southbank, Victoria, AU;
Inventors:
Ian J. Constable, Mosman Park, AU;
P. Elizabeth Rakoczy, Scarborough, AU;
Chooi-May Lai, Waterford, AU;
Thomas W. Chalberg, Jr., Redwood City, CA (US);
Assignee:
Avalanche Australia Pty Ltd., Southbank, AU;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/45 (2006.01); A61K 48/00 (2006.01); A61K 38/17 (2006.01); C12N 15/86 (2006.01); A61K 49/00 (2006.01); A61B 3/032 (2006.01); A61K 35/761 (2015.01); C12N 7/00 (2006.01); A61K 45/06 (2006.01); A61K 31/7088 (2006.01); C07K 14/71 (2006.01); C12N 9/12 (2006.01); C07K 16/22 (2006.01); C07K 16/08 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/45 (2013.01); A61B 3/032 (2013.01); A61K 31/7088 (2013.01); A61K 35/761 (2013.01); A61K 38/179 (2013.01); A61K 45/06 (2013.01); A61K 48/00 (2013.01); A61K 48/0075 (2013.01); A61K 49/0004 (2013.01); C07K 14/71 (2013.01); C07K 16/081 (2013.01); C07K 16/22 (2013.01); C12N 7/00 (2013.01); C12N 9/12 (2013.01); C12N 15/86 (2013.01); C12Y 207/10001 (2013.01); C12Y 207/10002 (2013.01); A61K 9/0048 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/73 (2013.01); C07K 2319/32 (2013.01); C12N 2710/14044 (2013.01); C12N 2750/14141 (2013.01); C12N 2750/14142 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14171 (2013.01); C12Y 207/10 (2013.01);
Abstract
The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.